Yüklüyor......
Phase 2 Trial of the CDK4 inhibitor Palbociclib (PD0332991) at 125 mg dose in Well-Differentiated or Dedifferentiated Liposarcoma
IMPORTANCE: Over 90% of well-differentiated/de-differentiated liposarcomas (WD/DDLS) have CDK4 amplification. The selective CDK4/CDK6 inhibitor palbociclib inhibits growth and induces senescence in liposarcoma cell lines and xenografts. Our prior phase 2 study demonstrated that treatment with palboc...
Kaydedildi:
| Yayımlandı: | JAMA Oncol |
|---|---|
| Asıl Yazarlar: | , , , , , , , , , , , , |
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
2016
|
| Konular: | |
| Online Erişim: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4991028/ https://ncbi.nlm.nih.gov/pubmed/27124835 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1001/jamaoncol.2016.0264 |
| Etiketler: |
Etiketle
Etiket eklenmemiş, İlk siz ekleyin!
|